Pooled phenotypic CRISPR screening enables the identification of synergistic drug combinations for cancer therapy

Pooled CRISPR–Cas9 knock-out screens are valuable tools for new drug target identification. However, it can be challenging to find potential new therapeutic interactions through looking for gene deletions that cause cell death in the presence of a given drug.

A powerful adaptation of CRISPR screening is provided by the coupling of pooled NGS-linked screening strategies to phenotypic measurements. By using this combination of techniques, the screening strategy can be targeted to detect genes which drive complex biological responses by a biomarker signal read out and then deep sequencing sorted populations separately.

Read this application note to learn more about how a pooled phenotypic CRISPR screening can be applied to identify synergistic drug combinations for cancer therapy.

For research use only. Not for use in diagnostic procedures.